The aberrant activation of RAS-BRAF-MEK1/2-ERK1/2 kinase signaling pathway, which mediates the extracellular signals into the nucleus, contributes to thyroid carcinoma by increasing cell proliferation, survival, and metastasis. The gene discussed is BRAF; the disease is thyroid gland carcinoma.